• Health Care

DCGI approved Astra Zeneca’s Lynparza as a monotherapy for adjuvant treatment of patients with high-risk early breast cancer

·         Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer ·         New Data from OlympiA Phase…